California-based Aviir, Inc., has announced it will be extending its offered services with a comprehensive inherited cardiovascular disease genetic test menu. The MIRISK and MIRISK VP blood tests cover the major causes of cardiomyopathies, arrhythmias, and other genetically transmitted diseases that affect the heart and vasculature. Each test is available for both individual and familial testing, and two comprehensive panels are available to check for undiagnosed arrhythmia or cardiomyopathy. The MIRISK and MIRISK VP assessments identify individuals who are at risk of a cardiac event over the next five years.
“Aviir’s mission is to identify and prevent cardiovascular diseases, and subsequent deaths, through the best diagnostic means available,” says Doug Harrington, MD, the company’s CEO. “To this end, we’ve added a comprehensive list of inherited cardiovascular disease testing to our menu. This type of testing can be the difference between effective disease management and needless risk of sudden cardiac death.”
Genetic testing can help determine a successful course of treatment for the patient, as well as identify any familial testing needs resulting from a positive result. This information can lead a patient to make successful lifestyle changes and pursue therapy to live a healthy life despite the disease. Learn more about Aviir and the MIRISK solutions.
